Gland Pharma Strengthens Operations with New Senior Vice President

Gland Pharma Limited has appointed Prasadha Rao Lysetti as its new Sr. Vice-President and Head of Operations, effective April 6, 2026. Mr. Lysetti brings more than 25 years of extensive experience in pharmaceutical manufacturing and operations.

Leadership Boost for Operations

This appointment adds significant experience to Gland Pharma's senior leadership team. As Head of Operations, Mr. Lysetti will oversee critical manufacturing processes and supply chains. This role is vital for Gland Pharma, a major player in the global pharmaceutical injectables market, as it focuses on maintaining high production standards and driving operational efficiency.

Leadership Transitions at Gland Pharma

The company, an Indian generic injectable manufacturer and contract development and manufacturing organization (CDMO), has seen several leadership changes recently. The Chief Operating Officer, Satnam Singh Loomba, retired on March 31, 2026, and CEO Shyamakant Giri resigned effective April 30, 2026. Mr. Giri had succeeded Srinivas Sadu, who remains Executive Chairman. Earlier in February 2026, Dr. Jitendra Gangwal joined as Vice-President of Research and Development.

Focus on Manufacturing and Market Position

With extensive experience in pharmaceutical manufacturing, Mr. Lysetti's role is expected to reinforce Gland Pharma's operational leadership. This move signals a continued commitment to enhancing manufacturing efficiency and effectiveness across its facilities in India and Europe. In the competitive global market for generic injectables and CDMO services, strong operational management is crucial for maintaining Gland Pharma's position and expanding market share.

Challenges and Industry Context

Gland Pharma is also managing other business aspects. The company faces a Goods and Services Tax (GST) demand of ₹6.29 crore for FY19-20, which it plans to contest. The company's performance in FY23 was affected by supply chain disruptions, client inventory adjustments, and production shutdowns, which reduced margins and revenue. Concerns over pricing pressures and regulatory challenges have led some analysts to maintain 'Sell' ratings as of March 2026. Top Indian pharmaceutical peers, including Dr. Reddy's Laboratories, Sun Pharma, Cipla, and Zydus Lifesciences, also emphasize strong manufacturing capabilities and global reach. Investors will be monitoring how Mr. Lysetti's leadership impacts operational efficiency and output, and how Gland Pharma addresses past challenges and ongoing regulatory matters.